$2.0M
+$2.0M this year1 filing since 2026 · latest SAFE filed
RLL is a clinical-stage biopharmaceutical company in Lutherville, Maryland developing novel cancer therapeutics. Its lead asset, AOH1996, is a first-in-class oral small molecule that binds a central driver of cancer cell proliferation to block tumor growth, DNA repair, and replication while reportedly leaving normal cells largely unaffected. AOH1996 is in Phase 1 clinical trials, and the company also maintains a veterinary pipeline. RLL was co-founded by breast surgical oncologist Dr. Lauren Schnaper, who serves as president.
What sets it apart
AOH1996 has a first-in-class mechanism that targets a protein central to cancer cell proliferation, showing high selectivity for cancer over normal cells, low reported toxicity, synergy with existing chemotherapies at lower doses, and resistance to the escape pathways tumors typically develop.
A first-in-class oral small-molecule anticancer drug candidate that binds a central driver of cancer cell proliferation, blocking cancer cell growth, DNA repair, and replication.
